Short answer: Cosentyx (secukinumab) has a long-term safety profile that is generally favorable and similar in overall infection/malignancy risk to other biologics, but with some distinct signals tied to IL-17 blockade.
Key differences to know
- Infections
- Cosentyx: Common infections (e.g., cold/upper respiratory infections). Serious infections are possible but rates are generally low and in line with other biologics.
- IL-17 inhibitors vs TNF inhibitors: TNF inhibitors tend to have a higher risk of serious infections and tuberculosis (TB) reactivation. IL-17 inhibitors like secukinumab have a lower TB risk but can still cause infections.
- Candida infections: IL-17 pathway is important for mucocutaneous defense against Candida, so mucocutaneous candidiasis (thrush) appears more with IL-17 inhibitors than with some other classes. These are usually mild and treatable.
- Inflammatory bowel disease (IBD)
- Cosentyx: There is a signal that IL-17 blockade can be associated with new-onset IBD or flares in people with Crohn’s disease or ulcerative colitis. It’s generally avoided or used with caution in active IBD.
- Compared with other biologics: TNF inhibitors are often used to treat IBD, ustekinumab (IL-12/23 inhibitor) has a different safety/efficacy profile for IBD. If you have known IBD, your doctor will weigh these risks carefully.
- Immunogenicity (antidrug antibodies)
- Secukinumab: Tends to have low rates of anti-drug antibodies that affect efficacy or safety. This means long-term effectiveness is usually maintained without loss of response due to antibodies.
- Malignancy risk
- Across long-term data, secukinumab has not shown a clear signal for increased malignancy compared with the general psoriasis/psoriatic arthritis populations and with other biologics. Monitoring remains standard as with all biologics.
- Other safety signals
- Injection-site reactions and headaches are among the common, usually mild, AEs.
- Live vaccines are generally contraindicated during biologic therapy; consult your clinician about vaccination timing.
- Pregnancy: data are limited; discuss family planning with your clinician if relevant.
How it differs from a few other common biologics (high level)
- TNF inhibitors (e.g., adalimumab, infliximab): Higher risk of serious infections and TB reactivation; broader concern for heart failure in some patients; different infection and malignancy safety signals.
- IL-12/23 inhibitor (ustekinumab): Different infection risk profile; no strong signal for mucocutaneous candidiasis; may be preferred in patients with or at risk for IBD, depending on case.
- IL-17 receptor blocker (brodalumab): Some safety concerns historically around suicidality; not a concern with secukinumab, but safety profiles differ across agents.
- JAK inhibitors (e.g., tofacitinib): Oral small molecules with different safety considerations (e.g., herpes zoster risk, blood lipids changes, thrombotic risks) and typically not in the same class as biologics.
Practical takeaways
- If you have Crohn’s disease or a history of IBD, discuss carefully with your doctor whether Cosentyx is appropriate.
- Be vigilant for signs of infection (fever, persistent cough, chills, red/swollen area at injection site) and for signs of candidiasis (mouth/vaginal itching or unusual discharge).
- TB screening and routine vaccinations should be addressed before starting therapy; avoid live vaccines while on therapy.
- Long-term safety data up to several years show no unexpected new risks with Cosentyx, but any biologic requires ongoing monitoring.
If you want, tell me which specific biologic you’re comparing Cosentyx to (e.g., adalimumab, ustekinumab, ixekizumab, etc.). I can tailor a side-by-side safety comparison. Also, I can summarize the most recent label guidance or pivotal long-term safety studies for you.